作者: Sutherland, Rachel ; Lenton, Simon ; Agramunt, Seraina ; Bruno, Raimondo ; Dietze, Paul ; Thomas, Natalie ; Peacock, Amy ; Salom, Caroline ; Price, Olivia ; Akhurst, Jane ; Colledge-Frisby, Samantha ; Gibbs, Daisy

BACKGROUND:

Examining take-home naloxone (THN) uptake using a 'cascade of care' framework could help identify targets for increasing THN training and carriage among people who may witness or experience opioid overdose. We describe the THN cascade and factors associated with engagement among people who inject drugs.

METHODS:

People aged ≥18 years in Australia who inject drugs were interviewed from 2020 to 2022, reporting lifetime THN awareness and acquisition and past-month carriage. We examined factors associated with engagement using multivariable logistic regression.

RESULTS:

Of 2,149 participants (64 % men, mean age 44.5), 85 % had heard of naloxone, of whom 76 % were aware of THN programs. Of these, 72 % had ever participated in THN training/brief education, 92 % of whom had acquired THN. Of those who had ever acquired THN and reported past-month opioid use, 63 % always/often carried THN when using opioids. Past six-month opioid agonist treatment (OAT) (adjusted odds ratio [AOR] 2.55; 95 %CI 1.91-3.42) and ≥daily injecting (1.32; 1.01-1.73) were associated with awareness. OAT (1.79; 1.38-2.33), past-year opioid overdose (1.68; 1.18-2.42) and older age (1.02; 1.00-1.03) were associated with acquisition. Primarily injecting methamphetamine (versus heroin) in the past month was associated with lower awareness (0.43; 0.31-0.58) and acquisition (0.59; 0.44-0.78). Reporting no accommodation (squatting/sleeping rough) was associated with reduced odds of carriage (0.46; 0.24-0.88).

CONCLUSION:

Participants reported high THN awareness and acquisition, with lower carriage. Future efforts should focus on improving THN access and reducing barriers to carriage, particularly for people experiencing homelessness or who primarily inject non-opioids.

2024-10-01·ARCHIVES OF PSYCHIATRIC NURSING

Reasons for using methamphetamine: Systematic review

Review

作者: Hançer Tok, Hümeyra ; Tokur Kesgin, Makbule

BACKGROUND AND OBJECTIVES:

Use of methamphetamine has increased in the last decade. The reasons for using methamphetamine vary according to the characteristics of the users. The literature includes review studies on methamphetamine use; however, no systematic review on the reasons for using methamphetamine was found. This study aims to determine the reasons for methamphetamine use through a systematic review of the literature.

METHOD:

The data from a systematic review of the literature review were reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Science Direct, Ovid-Medline, and Google Scholar databases were scanned using the keywords "methamphetamine", "crystal", "meth", "addiction", "reason for use", and "motivation to use". The articles (n = 25,004) were reviewed based on the inclusion and exclusion criteria, and 21 articles were finally selected for this study.

RESULTS:

The reasons for using methamphetamine included improving performance, staying awake, increasing sexual performance and impulses, reducing the effects of withdrawal from other substances, coping with problems, socializing, having fun, and coping with pain and discomfort.

DISCUSSION AND CONCLUSIONS:

Methamphetamine users typically take this drug to provide performance enhancement and cope with problems in different areas. It is recommended to inform the users correctly about methamphetamine, to teach effective methods of coping with withdrawal, and to carry out supply prevention studies.

SCIENTIFIC SIGNIFICANCE:

This is the first systematic literature review to reveal the reasons why people take methamphetamine. Revealing these causes is very important in terms of intervention (basic, primary, secondary, and tertiary protection) strategies.

2024-10-01·JOURNAL OF MASS SPECTROMETRY

Improved Discrimination of Mass Spectral Isomers Using the High‐Dimensional Consensus Mass Spectral Similarity Algorithm

Article

作者: Rabe Andriamaharavo, Nirina ; Kearsley, Anthony J. ; McGlynn, Deborah F.

ABSTRACT:

This study employs a high‐dimensional consensus mass spectral (HDCMS) similarity scoring technique to discriminate isomers collected using an electron ionization mass spectrometer. The HDCMS method was previously introduced and applied to the discrimination of mass spectra of constitutional isomers, methamphetamine and phentermine, collected with direct analysis real‐time mass spectrometry (DART‐MS). The method formulates the problem of discriminating mass spectra in a mathematical Hilbert space and is hence called “high dimensional.” It requires replicate mass spectra to build a Gaussian model and evaluate the inner products between these functions. The resulting measurement variability is used as a signature by which to discriminate spectra. In this work, HDCMS is tested on electron impact ionization (EI) mass spectra of 7 terpene and terpene‐related (C10H16 and C10H14) isomers with experimental retention indices that differ by less than 30 and with traditional cosine similarity scores greater than 0.9, on a scale of 0 to 1, when compared with at least one other compound in the test set. Using identical instrument parameters, 15 replicate gas chromatography–electron ionization–mass spectrometry (GC‐EI‐MS) spectra of each isomer were collected and separated into distinct library and query sets. The HDCMS algorithm discriminated each isomer, indicating the method's potential. Because the method requires replicate measurements, observations from a simple heuristic study of the number of replicates required to discriminate these isomers is presented. The paper concludes with a discussion of compound discrimination using HDCMS and the benefits and drawbacks of applying the method to EI‐MS data.

101

项与甲基安非他明相关的新闻（医药）

2024-09-19

·GlobeNewswire-Health Care

Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights

- Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year – - As of June 30, 2024, the Company had $6.30 million in cash - NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced its financial results for the fiscal fourth quarter and full-year ended June 30, 2024, and provided a business update. Fiscal fourth quarter revenue totalled $0.73 million, an increase of 64% compared to the same period the prior year, and full-year revenue totalled $3.11 million, an increase of 148% compared to the prior fiscal year. As of June 30, 2024, the Company had $6.30 million in cash. “Our fiscal 2024 results reflect the dedication we have invested as a team to really drive the business forward,” said Harry Simeonidis, President and CEO at INBS. “Customer demand has remained strong, with orders increasing across the board as more businesses turn to our drug screening technology to safeguard their workforce and uphold their reputation for prioritizing safety. Our progress is promising, and we are continuously refining our strategy to ensure sustainable and profitable long-term growth. We remain on track for our planned FDA 510(k) submission in the fourth calendar quarter of this year and look forward to the opportunities this will unlock in 2025.” In addition, INBS reported a 20% increase in cartridge sales and a 26% increase in reader sales for the fiscal year ended June 30, 2024, compared to the prior fiscal year. With each reader needing a continuous supply of cartridges for testing, recurring revenue from cartridge sales has been a key driver in INBS’ continued growth across its active customer base of more than 400 businesses. Spiro Sakiris, CFO at INBS, commented, “We closed out fiscal 2024 with strong results. We have ensured revenue growth through concentrated expansion of our footprint, and with over 1,000 readers now installed, we are generating consistent and recurring revenue from cartridge sales. Awareness of our technology is growing, and we are seeing the results. Our next step is strategic geographical expansion, allowing us to enter new markets and further grow our customer network.” Operational Highlights for Fiscal 2024: On June 28, 2024, the Company announced the successful completion of the in-clinic portion of its Pharmacokinetic (PK) study, a core component of the Company’s clinical study plan for its 510(k) pathway for clearance by the United States Food and Drug Administration (FDA). The Company expects to complete the full PK study in the third calendar quarter of 2024.On April 11, 2024, the Company announced that its wholly owned subsidiary, Intelligent Fingerprinting Limited, had been granted a new European patent with unitary effect for its DSR-Plus Cartridge Reader, bringing the patent into effect in 17 European countries.On February 28, 2024, the Company announced its partnership with Cliantha Research to perform a pharmacokinetic (PK) study as part of its FDA 510(k) clinical study plan. Initiating the clinical studies plan represented a critical milestone for the Company.In December 2023, the National Association of Testing Authorities (NATA) accredited the Company’s laboratory partner, Racing Analytical Services Limited (RASL), to perform its fingerprint confirmatory drug testing procedure. This accreditation serves as an independent benchmark for technical validation, demonstrating the Company’s commitment to product quality, safety, and reliability for its customers.During the year, the Company announced new partnerships with Robinson Brothers, DGP Plc and James Jones & Sons, VKVP Haulage, State Road Constructions, Titan Cranes and Rigging Pty Ltd. and P&O Ferries. Additionally, the Company reported the successful completion of 25,000 Intelligent Fingerprinting tests by its existing customer, Auctus Management Group. Continued customer account growth demonstrates the strength of the Company’s proprietary fingerprint sweat-based technology in the market. The Company looks to continue this momentum and expand into new customer segments and geographical regions throughout the Asia-Pacific region (the “APAC Region”), Europe, South America and the United Arab Emirates.On October 24, 2023, the Company announced its expansion into the New Zealand market, expanding its global footprint and extending the reach of its drug screening product. Expansion into New Zealand demonstrates the Company’s ability to introduce its product in new markets. The Company aims to continue growth in new markets, offering an alternative and innovative solution that places a strong emphasis on operational efficiency, fitness for duty, employee privacy and dignity.On September 27, 2023, the Company announced that its Intelligent Fingerprinting Drug Screening business had obtained recertification for the latest ISO 13485: 2016 harmonized quality management system standard for the medical device industry. The recertification took effect on October 14, 2023, and is valid for three years. ISO 13485:2016 is the international standard for medical devices quality management system certification and is a requirement for medical device manufacturers operating across key regions, including the USA, Canada, Europe, Japan, Singapore, Malaysia and Saudi Arabia.On September 21, 2023, the Company announced the successful debut of its Intelligent Fingerprinting Drug Screening System at the 2023 Workplace Health & Safety Show in Sydney, Australia.On September 8, 2023, the Company announced the successful completion of a key development milestone in its plans to add ketamine and tramadol to its Intelligent Fingerprinting Drug Screening System. New assays for testing both drugs have passed the Company’s initial design phase and are ready for scale-up and transfer to manufacture in preparation for potential clinical trials. After completing these activities and successful clinical trials, the assays can be added to the panel of substances detected by the Company’s proprietary drug screening system.On August 1, 2023, the Company announced that it had secured 8 new customers across various locations throughout Australia, which collectively employ over 10,000 individuals, within just two months of launching its Intelligent Fingerprinting Drug Screening System in Australia.On July 6, 2023, the Company announced that it has signed a distribution agreement with Chile-based company TSCOM SPA for its Intelligent Fingerprinting Drug Screening System, increasing the product’s availability across South America. The Company further announced that it received its first order under this agreement, from a Chile-based electrical distribution company. Fourth Quarter and Full Year Ended June 30, 2024, Financial Results All amounts are expressed in U.S. dollars unless indicated otherwise. The Company’s revenue increased by 148% to $3.11 million for the fiscal year ended June 30, 2024, compared to $1.26 million for the fiscal year 2023. The increase in revenue is due to market demand, increasing brand and product awareness, and continued expansion of the Company’s customer base. Throughout fiscal year 2024, the Company launched its Intelligent Fingerprinting Drug Screening System in the APAC region through its subsidiary, Intelligent Bio Solutions (APAC) Pty Ltd, adding to its existing commercialization and marketing efforts in the United Kingdom and Europe. Loss from operations was $10.28 million for the 2024 fiscal year, compared to $12.59 million in the prior fiscal year. This improvement was primarily driven by an increase in revenue of $1.85 million and gross profit of $1.10 million, complemented by a reduction in total operating expenses of $1.53 million. The net loss attributable to INBS for fiscal year 2024 was $10.16 million, compared to $10.63 million in the prior fiscal year. This is mainly due to a fair value gain on the revaluation of financial instrument of $0.18 million in the fiscal year 2024 compared to $2.15 million in the prior fiscal year. As of June 30, 2024, the Company’s cash and cash equivalents totalled approximately $6.30 million. Financial Tables to Follow Intelligent Bio Solutions Inc.Consolidated Balance Sheets* As of June 30, As of June 30, 2024 2023 ASSETS Current assets Cash and cash equivalents $6,304,098 $1,537,244 Accounts receivable, net 429,704 293,861 Inventories, net 777,537 979,907 Research and development tax incentive receivable 525,332 498,758 Other current assets 497,572 552,791 Total current assets 8,534,243 3,862,561 Property and equipment, net 565,850 690,175 Operating lease right of use assets 306,744 546,475 Intangible assets, net 4,372,026 5,255,401 Total assets $13,778,863 $10,354,612 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities Accounts payable and accrued expenses $1,704,568 $2,610,028 Current portion of operating lease liabilities 274,834 223,447 Current portion of deferred grant income 2,486,668 2,338,057 Current employee benefit liabilities 469,381 358,942 Current portion of notes payable 515,282 353,211 Total current liabilities 5,450,733 5,883,685 Employee benefit liabilities, less current portion 63,615 24,902 Operating lease liabilities, less current portion 81,324 356,165 Notes payable, less current portion - 402,862 Total liabilities 5,595,672 6,667,614 Commitments and contingencies Shareholders’ equity Common stock, $0.01 par value, 100,000,000 shares authorized, 3,456,000 and 194,200 shares issued and outstanding at June 30, 2024 and 2023, respectively* 34,557 1,942 Treasury stock, at cost, 116 shares as of June 30, 2024 and 2023, respectively* (1) (1)Additional paid-in capital 60,971,740 46,180,112 Accumulated deficit (51,964,332) (41,807,573)Accumulated other comprehensive loss (712,614) (575,496)Total consolidated Intelligent Bio Solutions Inc. equity 8,329,350 3,798,984 Non-controlling interest (146,159) (111,986)Total shareholders’ equity 8,183,191 3,686,998 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $13,778,863 $10,354,612 *Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the 1-for-12 Reverse Stock Split on January 26, 2024, throughout the consolidated financial statements unless otherwise stated. The accompanying notes are an integral part of these consolidated financial statements. Intelligent Bio Solutions Inc.Consolidated Statements of Operations and Other Comprehensive Income (Loss)* Year ended June 30, 2024 2023 Revenue $3,111,781 $1,256,872 Cost of revenue (exclusive of amortization shown separately below) (1,686,155) (930,204)Gross profit 1,425,626 326,668 Other income: Government support income 424,776 737,628 Operating expenses: Selling, general and administrative expenses (9,258,496) (8,026,703)Development and regulatory approval expenses (1,673,806) (507,424)Depreciation and amortization (1,201,274) (966,732)Goodwill impairment - (4,158,670)Total operating expenses (12,133,576) (13,659,529)Loss from operations (10,283,174) (12,595,233) Other income (expense), net: Interest expense (167,140) (223,534)Realized foreign exchange loss (1,178) (9,829)Fair value gain on revaluation of financial instrument 175,738 2,154,365 Interest income 84,822 9,676 Total other income, net 92,242 1,930,678 Net loss (10,190,932) (10,664,555)Net loss attributable to non-controlling interest (34,173) (32,835)Net loss attributable to Intelligent Bio Solutions Inc. $(10,156,759) $(10,631,720) Other comprehensive income (loss), net of tax: Foreign currency translation gain/ (loss) (137,118) 212,639 Total other comprehensive income (loss) (137,118) 212,639 Comprehensive loss (10,328,050) (10,451,916)Comprehensive loss attributable to non-controlling interest (34,173) (32,835)Comprehensive loss attributable to Intelligent Bio Solutions Inc. (10,293,877) (10,419,081) Net loss per share, basic and diluted* $(6.38) $(127.00)Weighted average units outstanding, basic and diluted * 1,592,746 83,717 The accompanying notes are an integral part of these consolidated financial statements. *Common Stock and per share amounts have been retroactively adjusted to reflect the decreased number of shares resulting from the 1-for-12 Reverse Stock Split on January 26, 2024, throughout the consolidated financial statement unless otherwise stated. About Intelligent Bio Solutions Inc.  Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company’s biosensor platform has the potential to test for various indications, ranging from immunological conditions to communicable diseases. The Company’s current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.   For more information, visit: http://www.ibs.inc/   Forward-Looking Statements:  Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.  Company Contact:  Intelligent Bio Solutions Inc.  info@ibs.inc  Investor & Media Contact:   Valter Pinto, Managing Director   KCSA Strategic Communications   PH: (212) 896-1254   INBS@kcsa.com

财报

2024-09-11

·GlobeNewswire-Health Care

Intelligent Bio Solutions to Participate in the Sidoti Small-Cap Virtual Conference on September 18-19, 2024

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a leader in non-invasive drug testing technology, today announced that its management team will participate in the Sidoti Small-Cap Virtual Conference being held on September 18-19, 2024. Presentation DetailsDate: Thursday, September 19, 2024Time: 2:30 p.m. Eastern Time Registration/Webcast Link: https://sidoti.zoom.us/webinar/register/WN_7jmynN8bTrqwS7q4Aupv7w For more information about the conference, or to schedule a one-on-one meeting with the INBS management team, please contact your Sidoti representative or email KCSA Strategic Communications at INBS@ksca.com. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company’s biosensor platform has the potential to test for various indications, ranging from immunological conditions to communicable diseases. The Company’s current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.  For more information, visit: http://www.ibs.inc/ Company Contact: Intelligent Bio Solutions Inc. info@ibs.inc LinkedIn | Twitter Investor & Media Contact:Valter Pinto, Managing DirectorKCSA Strategic CommunicationsPH: (212) 896-1254INBS@kcsa.com

2024-09-10

·PRNewswire

Clear Scientific Reports Positive Topline Phase 1 Clinical Trial Data for CS-1103, a Potential First-in-Class Therapeutic for Meth and Fentanyl Overdose

The Phase 1 study for CS-1103 met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events Phase 2 studies for the treatment of methamphetamine and fentanyl overdose are planned for early 2025 CAMBRIDGE, Mass., Sept. 10, 2024 /PRNewswire/ -- Clear Scientific, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for conditions and diseases caused by an excess of harmful substances in the body, today announced positive topline data from the First-in-Human Phase 1 clinical trial of its therapeutic CS-1103 that demonstrate a favorable safety and tolerability profile. All thirty-two healthy participants recruited, divided into 4 cohorts, completed the Phase 1 single ascending dose, randomized, double-blinded, placebo-controlled, safety, tolerability and pharmacokinetics study. In this study, single doses of CS-1103, administered via intravenous injection, were well tolerated. There were no serious adverse events reported. The Phase 1 study supports the dose requirement for the Phase 2 studies on meth and fentanyl overdose, planned for early 2025. "The phase 1 results clear a critical hurdle, as together with the pre-clinical studies, convincingly demonstrate both safety and efficacy of CS-1103. Based on these strong results, we are working toward an accelerated registration pathway with Phase 2 studies to begin in early 2025. We thank the National Institute on Drug Abuse (NIDA) of the NIH for their continued support," said Shekar Shetty, Clear Scientific CEO. About the Overdose Epidemic The US overdose crisis continues unabated, with 1.9M emergency department (ED) visits and over 100,000 deaths annually. According to the CDC, drug overdose mortality rates are at the highest level they've ever been, and overdose is the leading cause of death for Americans under the age of 50. There are currently approved medications for opioid overdose, however, there are no approved treatments for overdose with stimulants or overdoses that result from drug combinations. About CS-1103 CS-1103 is a first-in-class injectable small molecule sequestrant that immediately binds to and inactivates target compounds, rapidly reversing their toxic effects and accelerating clearance into urine. Clear Scientific is developing CS-1103 for treatment of overdose and selected metabolic, central nervous system, and neurodegenerative disorders. About Clear Scientific Clear Scientific, a clinical-stage biopharmaceutical company co-founded by George Whitesides of Harvard University, is pioneering a new paradigm for treatment of conditions and diseases that involve an excess of specific compounds in the body. This approach focuses on development of highly selective, small molecule sequestrants that bind, immediately inactivate, and rapidly clear excess compounds from the body. Research reported in this press release was supported by the National Institute on Drug Abuse of the National Institutes of Health under award number U01DA053054. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. SOURCE Clear Scientific

临床1期临床结果

100 项与甲基安非他明相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08187	甲基安非他明	N06BA03	DB01577

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑损伤	临床1期	美国	Sinapis Pharma, Inc.	-
脑损伤	临床1期	-	The University of Montana	-
脑损伤	临床1期	-	Sinapis Group	-
脑卒中	临床1期	美国	Sinapis Pharma, Inc.	-
脑卒中	临床1期	-	Sinapis Group	-
脑卒中	临床1期	-	The University of Montana	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03790618 (ESP, CTgov)	临床1期	-	36	3,4-Methylenedioxymethamphetamine+methamphetamine (Placebo)	鏇繭膚範獵膚窪觸選鹹(夢構鏇齋積積廠窪鹹蓋) = 醖餘蓋廠夢淵衊蓋鏇壓醖願築鑰膚夢壓築齋淵 (憲廠糧範廠糧鑰窪窪糧, 糧蓋夢鹹糧廠選鑰膚選 ~ 構簾構餘積遞蓋鹽願範) 更多	-	2024-01-05
				3,4-Methylenedioxymethamphetamine+methamphetamine (Low Dose MDMA)	鏇繭膚範獵膚窪觸選鹹(夢構鏇齋積積廠窪鹹蓋) = 餘衊築憲網膚蓋網簾願醖願築鑰膚夢壓築齋淵 (憲廠糧範廠糧鑰窪窪糧, 膚獵願窪願願糧衊壓衊 ~ 觸窪艱壓艱築憲鹹醖鏇) 更多
NCT04178993 (CTgov)	临床1期	甲基苯丙胺依赖	8	Placebo oral capsule+Methylphenidate+Methamphetamine (Placebo Comparator: Placebo)	選顧衊壓廠製襯觸繭憲(範網憲製憲築積齋鹹構) = 鑰鹹襯廠醖觸鑰顧構構壓壓選憲製廠艱繭壓壓 (構淵獵衊選齋積糧膚範, 壓鏇淵齋齋衊鏇糧鹹夢 ~ 觸獵夢築壓膚選壓簾鹹) 更多	-	2023-01-09
				Placebo oral capsule+Methylphenidate+Duloxetine+Methamphetamine (Active Comparator: Duloxetine)	獵窪網範廠醖糧選鏇網(憲範衊鬱範遞壓鑰餘醖) = 壓壓繭醖艱鏇襯憲鹹構鏇襯窪顧積獵範觸簾構 (觸廠窪簾憲壓襯築壓廠, 鹹選餘願艱窪觸築獵觸 ~ 淵憲簾願構積遞範構憲) 更多
ESC2019	N/A	扩张型心肌病	-	methamphetamine	夢窪窪繭鹽網蓋觸積壓(艱艱積鬱憲夢夢構糧積) = 膚餘鏇艱網鹹選艱淵築範淵糧鏇獵鹽鹽獵廠艱 (膚廠壓鬱積製廠窪衊鑰 ) 更多	-	2019-09-02
ISC2019	N/A	脑出血	596	Patients with UDS for methamphetamines	簾簾鑰獵鬱製繭醖廠襯(觸憲鹽襯積鏇鑰憲製範) = 顧範獵襯淵襯憲選襯膚獵選壓簾簾簾憲窪蓋構 (製顧糧廠艱網網構範窪 )	-	2019-02-01
				Patients without UDS for methamphetamines	簾簾鑰獵鬱製繭醖廠襯(觸憲鹽襯積鏇鑰憲製範) = 窪糧製糧鬱範鏇製壓襯獵選壓簾簾簾憲窪蓋構 (製顧糧廠艱網網構範窪 )
NCT02323048 (CAM, CTgov)	N/A	物质滥用	90	placebo+methamphetamine (Paired, Low Reward)	鏇積窪膚廠顧壓廠簾網(築願齋餘鹽鑰獵壓簾顧) = 範繭繭餘膚築鹽積憲觸襯網憲壓鹹鹽鬱願鹹廠 (遞憲齋糧築構醖遞艱艱, 餘憲積壓壓鏇選積齋鑰 ~ 鏇願願醖鹹願網願鹽糧) 更多	-	2018-07-26
				placebo+methamphetamine (Paired, High Reward)	鏇積窪膚廠顧壓廠簾網(築願齋餘鹽鑰獵壓簾顧) = 範廠範壓範醖淵範憲淵襯網憲壓鹹鹽鬱願鹹廠 (遞憲齋糧築構醖遞艱艱, 鹽觸構鏇顧願廠選觸製 ~ 壓築齋遞製積鏇構願蓋) 更多
MDS2017	N/A	-	-	Methamphetamine users (males)	齋遞窪蓋憲蓋夢鑰網繭(構鏇餘衊遞餘觸醖選衊) = 壓蓋製遞範憲艱淵簾觸餘夢膚選醖窪齋蓋膚遞 (顧膚繭願鬱襯鹹鑰顧淵 )	-	2017-06-04
				Methamphetamine users (females)	齋遞窪蓋憲蓋夢鑰網繭(構鏇餘衊遞餘觸醖選衊) = 壓鹽鑰範淵廠鬱鬱壓淵餘夢膚選醖窪齋蓋膚遞 (顧膚繭願鬱襯鹹鑰顧淵 )
AAN2017	N/A	脑出血 methamphetamine positive toxicology screen	-	methamphetamine	簾蓋襯積選願鹽製膚糧(膚簾網獵憲襯網憲鹽齋) = 餘淵鬱鏇構繭範鬱鏇醖窪壓築顧顧簾衊淵衊膚 (憲鬱膚遞蓋觸網衊鑰壓 )	积极	2017-04-18